PDCD1 and cancer: In cancer models, blocking BTLA in combination with other immune checkpoint inhibitors, such as PD-1 or bispecific antibodies, enhances T cell-mediated tumor eradication, suggesting a promising therapeutic strategy.81,82 Therefore, targeting BTLA may enhance T cell activation and restore anti-tumor immune responses.